HomeClinical TopicsFDA approves Synribo for chronic myelogenous leukemia
Clinical TopicsDrugs and DevicesHealthcare & TechnologyOncologyNewsWeb Exclusives

FDA approves Synribo for chronic myelogenous leukemia

Author(s):

On Oct. 26, the U.S. Food and Drug Administration (FDA) approved Synribo (omacetaxine mepesuccinate) for the treatment of adults with chronic myelogenous leukemia. Synribo blocks certain proteins that promote the development of cancerous cells. Read more.

Previous articleStudy: Reporting medical errors may help reduce them in multi-site clinical practices
Next articleWhat a Great Week For Midlife Women And Menopausal Hormone Therapy – Keeps And Dops!

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

Powered by  HCM   www.HealthComMedia.com

© 2021 HealthCom Media All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder.